Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions by Yang, Lingyun
Georgia State University
ScholarWorks @ Georgia State University
Chemistry Theses Department of Chemistry
8-8-2017
Design and Synthesis of Inhibitors of Hypoxia
Inducible Factor-1-mediated Functions
Lingyun Yang
applejing1277@gmail.com
Follow this and additional works at: http://scholarworks.gsu.edu/chemistry_theses
This Thesis is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Chemistry Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please
contact scholarworks@gsu.edu.
Recommended Citation
Yang, Lingyun, "Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions." Thesis, Georgia State
University, 2017.
http://scholarworks.gsu.edu/chemistry_theses/104
DESIGN AND SYNTHESIS OF INHIBITORS OF HYPOXIA INDUCIBLE FACTOR-1-
MEDIATED FUNCTIONS 
 
 
by 
 
 
LINGYUN YANG 
 
 
Under the Direction of Professor Binghe Wang 
 
 
ABSTRACT 
Hypoxia Inducible Factors (HIFs) are very important transcription factors that can respond to 
low oxygen concentrations in the cellular environment. Inhibition of HIF’s transcriptional 
activity represents a promising approach to new anticancer compounds. Herein, we describe the 
design and synthesis of a series of HIF-1 inhibitors. Evaluation of these inhibitors using a cell-
based luciferase assay led to the discovery compounds with sub-micromolar potency. 
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1 INTRODUCTION  
1.1 Purpose of the Study  
A tumor is an abnormal growth of body tissue. Malignant tumors or cancer 
represent a major threat to human health. Based on the GLOBOCAN database,[1] tens 
of millions of people are diagnosed with cancer around the world each year, and more 
than half of them die from it. Cancer is generally considered a name for a class of 
diseases with varying characteristics. As a result, treatment outcome varies and a cure 
is an elusive goal.[2] Although there are debates as to whether one can truly summarize 
certain traits as hallmarks of cancer,[3-4] one thing is true that malignant solid tumors 
are often accompanied by a state of hypoxic, or low oxygen, conditions, presumably 
due to their rapid growth and inadequate vascularization.[5] Such hypoxic states activate 
the expression of genes responsible for malignancy, aggressiveness, metastasis, and 
treatment-refractory properties.[6]  
 
1.2 Hypoxia Inducible Factor-1 Pathway 
Hypoxia Inducible Factors (HIF) are a family of transcription factors that regulate 
hypoxia-driven gene expression.[7-8] HIFs can be activated under hypoxic conditions 
and induce target genes that regulate adaptive biological processes such as cell 
motility, anaerobic metabolism and angiogenesis.[9] HIF-1 is the chief regulator in the 
response of growing tumor to hypoxia.[10] HIF-1 is a heterodimeric protein complex 
composed of α and β subunits, and HIF-1α plays a role as an oxygen-sensitive 
transcriptional activator while HIF-1β is constitutively expressed in the cell nucleus.[11-
13] In the presence of oxygen, HIF-1α can be destroyed rapidly through the ubiquition-
2 
proteasome pathway (UPP).[14] HIF-1α subunit is dihydroxylated at key proline residues 
within the oxygen dependent degradation domain (ODD) of HIF-1α. During this 
process, PHD2, a member of the prolyl hydroxylase family, along with 2-oxoglutarate, 
oxygen and Fe(II) are required to promote the hydroxylation of HIF-1α.[15-17] Following 
this process, HIF-1α can bind to the von Hippel Lindau tumor suppressor protein 
(pVHL) which can polyubiquitinate HIF-1α due to its E3-ubiquitin ligase activity, 
subsequently signaling degradation via the ubiquition-proteasome pathway (UPP).[18] 
Under hypoxic conditions, PHD2 activity is inhibited because of the reduction of 
oxygen, and HIF-1α accumulates rapidly and forms the HIF-1 dimer with HIF-1β, 
regulating the transcription of many genes in a cell.[19] With the help of cofactor p300, 
HIF-1 binds to the hypoxia-responsive element (HRE) sequence of DNA, and promotes 
the expression of a number of target genes such as vascular epidermal growth factor 
(VEGF) and erythropoietin (EPO), which help hypoxic cells survive.[20-22] Solid tumors 
need an increased blood supply to grow and spread to other organs and regions of the 
body, and overexpression of VEGF is able to develop the enhanced blood supply for 
them.[23] EPO has a role of controlling erythropoiesis or red blood cell production, and it 
can be used to treat anemia from kidney failure or cancer treatment.[24] Over 
expression of EPO is a factor that exhibits an anti-apoptotic action on numerous cells, 
including malignant ones.[25]  
 
3 
1.3 HIF-1 Inhibitors 
Recently, many anti-cancer compounds have been developed to inhibit the HIF 
pathway.[26] Some of them have been applied in the clinic successfully. The 2016 
Laskar award was given to three scientists: William Kaelin, Jr., Peter Ratcliffe, and 
Gregg Semenza, for their seminal contributions in oxygen sensing and associated 
biological implications, further demonstrating the importance of this area. Inhibition of 
HIF-1 can be achieved in many ways, including decreased HIF-1α mRNA levels, 
decreased HIF-1α protein synthesis, increased HIF-1α degradation, decreased HIF 
subunit heterodimerization, decreased HIF binding to DNA, and decreased HIF 
transcription activity.[27] Many drugs are in clinical trials to treat cancer by inhibition of 
HIF-1, and they exhibited molecular mechanisms of inhibiting HIF-1 at different 
steps.[28] For example, the prodrug AFP-464 (Figure 1) is already applied in phase I 
cancer trials, and it almost blocks HIF-1α protein expression completely and partially 
inhibits HIF-1α mRNA expression by decreasing both the stability and translation of 
HIF-1α mRNA.[29] 
 
Figure 1: Chemical Structure of AFP-464 
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Earlier, KCN1 (Figure 2) was discovered as a potent HIF-1 inhibitor without any 
signficant toxicity.[9]    
 
Figure 2: Structure and IC50 value of KCN1 
 
 
Based on KCN1, a new compound SRIV-64b (Figure 3) was designed and synthesized 
by our group. Compared to KCN1, IC50 of 0.59 μM (Figure 2), SRIV-64b was 
determined to have a lower IC50 value and was considered the most potent HIF-1 
inhibitor of this series synthesized previously.[9]    
 
 
Figure 3: Structure and IC50 value of SRIV-64b 
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1.4 HIF-1 Inhibitors Classes 
During the past several years, more than 200 compounds have been synthesized 
by our group. However, only less than half of the compounds in the library can be 
considered as potent HIF inhibitors. In order to find more patent HIF inhibitors, new 
scaffolds were needed. 
Natural products manassantin A and manassantin B (Figure 4), isolated from 
Saururus cernuus have been shown to inhibit HIF-1 in vitro at nanomolar 
concentrations.[30-32] With these natural products and our earlier HIF-1 inhibitors in 
mind,[9] we were interested in designing “hybrid” compounds as a new scaffold of 
potential HIF-1 inhibitors. As a result, lead compound 2 (Figure 5) was developed with 
the goal of achieving manassantin-like activity against HIF, while having a more facile 
synthetic route than manassantins. Compound 2 was synthesized and shown as a 
potent HIF inhibitor, and successfully demonstrated HIF inhibition in a luciferase assay 
in glioblastoma cells. Our goal was to design new analogues by modifying lead 
compound 2 and to test them for HIF inhibitory activity. Based on substituents at 
different positions on the phenyl ring, five classes of compounds were designed and 
synthesized (Figure 6).  
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Figure 4: Manassantin A and B 
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Figure 5: Lead compound structure and IC50 value 
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Figure 6: Analogues Designed 
 
2     CHEMISTRY DESIGN AND EXPERIMENTS 
This work includes compounds synthesized by Jalisa Ferguson* and Marquis Griffin#. 
12a, 14d, 9d, 9g, 19b, 17e and 22a were synthezied by Dr. Jalisa Holmes Ferguson*. 
14a and 9a were synthesized by Marquis Griffin#. 
 
2.1 Design 
In Class I, we are interested in exploring the effect of having an ortho-substitution 
on the phenyl ring of region A, while maintaining the methyl-protected catechol 
structure on the right. In doing so, we expect that the torsional angle defined by 
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O(hydroxyl)-C-C-C to be slightly perturbed by alkoxy substitution at the ortho position. 
In this class of compounds, we designed six analogues, and compared their different 
structures for structure activity relationship study. 
In Class II, we are interested in examining the effect of para-subtitutions. In this 
case, the torsional angle defined by O (hydroxyl)-C-C-C is not expected to be 
perturbed. However, the various substitutions would allow us to explore the favorable 
and unfavorable interactions between the binding pocket and the para-substituents of 
the phenyl ring. In addition, such substitutions may also perturb the electronic 
properties of the phenyl ring and to some degree the hydrophobicity of the moiety. The 
various substituents at the para-position may also allow us to explore additional 
functional group interactions. In Class III, we are interested in examining the effect of 
substituents at the meta-position while keeping the protected catechol the same on the 
right side. Similarly, class III can be compared with class II. In Class IV and V, we are 
interested in changing the protected catechol to protected pyragol, while sampling 
various substituents on the phenyl ring on the left side.  Below are the results of 
synthesis and biological evaluation. 
 
2.2 Chemistry 
2.2.1 Class I: Ortho-phenolic ether benzhydrol analogues. 
Class I analogues were synthesized in two steps: nucleophilic substitution 
followed by lithium-halogen exchange with subsequent addition to aldehyde. 2-
Hydroxybenzaldehyde (3) was reacted with the corresponding bromide to generate 
9 
compounds (4a-f). Compounds (6a-f) were generated using a lithium-halogen 
exchange reaction of bromide of 5 using n-butyllithium. The aryllithium generated was 
used in situ in the subsequent addition reaction with aldehydes 4a-f, yielding final 
compounds 6a-f.  
 
Scheme 1: Synthesis of ortho-phenolic ether benzhydrol analogues. 
 
 
R= allyl (4a, 6a), isopropyl (4b, 6b), propyl (4c, 6c), hexyl (4d, 6d), methylcyclohexyl 
(4e, 6e), and benzyl (4f, 6f).  
 
Reagents and Conditions: (a) RBr, K2CO3, DMF, 78 °C, overnight, 97-99% yield. (b) n-BuLi, 
THF, -78 °C, 1.5 hours; (c) 4, 2 hours, 55-69% yield. 
 
2.2.2 Class II: Para-phenolic ether benzhydrol analogues 
Synthesis of Class II analogues was achieved in either 2 or 4 steps. In Scheme 2, 
the intermediates 8a-c were prepared by reaction between 4-hydroxybenzaldehyde (7) 
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and bromide compounds. Next, lithium-halogen exchange of 5 using n-BuLi, followed 
by addition of aldehyde 8, afforded the final compounds 9a-c. In Scheme 3, for 
analogue 9g, di-tert-butyl dicarbonate was reacted with 2-(piperidin-4-yl)ethan-1-ol 10b 
under aqueous conditions to yield intermediate 11b. Tosylation of 11b with 4-
methylbenzenesulfonyl chloride under mild conditions yielded 12*. Next, the 
intermediates 14a#-d were prepared by reaction between 4-bromophenol (13) and 
compounds 12* or bromide compounds. Lastly, lithium-halogen exchange of 14 using 
n-BuLi, followed by addition of 3,4-dimethoxybenzaldehyde, afforded the final 
compounds 9d#-g*. 
  
Scheme 2: Synthesis of Para-phenolic ether benzhydrol analogues 9a-9c. 
 
 
R= isobutyl (8a, 9a), hexyl (8b, 9b), methylcyclohexyl (8c, 9c).  
 
Reagents and Conditions: (a) K2CO3, RBr, DMF, 78 °C, overnight, 95-97% yield. (b) n-BuLi, 
THF, -78 °C, 1.5 hours; (c) 8a-c, 2 hours, 54-71% yield. 
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Scheme 3: Synthesis of Para-phenolic ether benzhydrol analogues 9d#-9g* 
 
 
n=2 (10b, 11b, 12*) 
R= allyl (14a#, 9d#), isopropyl (14b, 9e), propyl (14c, 9f), (1-(tert-
butoxycarbonyl)piperidin-4-yl)ethyl (14d*, 9g*). 
 
Reagents and Conditions: (a) Boc2O, H2O, room temperature, overnight, 96% yield. (b) TsCl, 
NEt3, THF, room temperature, overnight, 86% yield. (c) K2CO3, 12; RBr, DMF, 90 °C, 5 hours, 
95-97% yield. (d) n-BuLi, THF, -78 °C, 1.5 hours; (e) 3,4-dimethoxybenzaldehyde, 2 hours, 54-
71% yield. 
 
2.2.3 Class III: Meta-phenolic ether benzhydrol analogues 
Class III analogues were synthesized as described in Schemes 4 and 5. In 
Scheme 4, the analogues were synthesized by alkylation of 3-hydroxybenzaldehyde 
(15) using the corresponding bromide to give intermediates 16a-b. Next, lithium-
halogen exchange of 5 using n-BuLi, followed by addition of aldehyde 16, afforded the 
final compounds 17a-b. In Scheme 5, for analogues 17c-e, the intermediates 19a-c 
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were prepared by reaction between 3-bromophenol (18) and bromide compounds. 
Next, analogues 17c-e were synthesized by lithium-halogen exchange as described 
above. 
 
Scheme 4: Synthesis of Meta-phenolic ether benzhydrol analogues 17a-17c. 
   
 
R= isobutyl (16a, 17a), isopropyl (16b, 17b), propyl (16c, 17c). 
 
Reagents and Conditions: (a) K2CO3, DMF, 78 °C, overnight, 92-96% yield. (b) n-BuLi, THF, -
78 °C, 1.5 hours; (c) 16a-c, 2 hours, 67-78% yield. 
 
Scheme 5: Synthesis of Meta-phenolic ether benzhydrol analogues 17d and 17e*. 
 
 
R= allyl (19a, 17d), hexyl (19b, 17e)*. 
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Reagents and Conditions: (a) K2CO3, DMF, 90 °C, 5 hours, 93-97% yield. (b) n-BuLi, THF, -78 
°C, 1.5 hours; (c) 3,4-dimethoxybenzaldehyde, 2 hours, 63-69% yield. 
 
2.2.4 Class IV: Ortho-benzyl ether benzhydrol analogues. 
Synthesis of Class IV analogues was achieved in either 2 or 3 steps. For 
analogues 22b and 22c, intermediates 11a-b were prepared by the same method as 
described above (Scheme 3). Benzylic ether intermediates 21 were synthesized by O-
alkylation with sodium hydride as the base and 2-bromobenzyl bromide (20). Final 
analogues 22a-c were synthesized using lithium-halogen exchange to generate the 
arylitihium, followed by addition to trimethoxyphenyl aldehyde. 
 
Scheme 6: Synthesis of ortho-benzyl ether benzhydrol analogues. 
 
 
n=1 (10a, 11a), 2 (10b, 11b)  
R= phenyl (21a, 22a*), (1-(tert-butoxycarbonyl)piperidin-4-yl)methyl (21b, 22b), (1-(tert-
butoxycarbonyl)piperidin-4-yl)ethyl (21c, 22c).  
 
Br
Br
Br
O
OH
O
O
O
O
R
b c, d
21 2220
N
H
OH a
10 11
n
NBoc
OHn
R
14 
Reagents and Conditions: (a) Boc2O, H2O, room temperature, overnight, 98-99% yield. (b) 
ROH; 11a-11b, NaH, DMF, 0 °C-rt, overnight, 96-98% yield. (c) n-BuLi, THF, -78 °C, 1.5 hours; 
(d) 3,4,5-trimethoxybenzaldehyde, 2 hours, 59-71% yield. 
 
2.2.5 Class V: Tri-substituted phenolic ether benzhydrol analogues. 
Class V analogues were synthesized in two steps. 4-Bromo-2-methylphenol (23) 
was reacted with bromide compounds to form the ether intermediates 24a-f via 
nucleophilic substitution. Next, analogues 25a-f were synthesized using lithium-
halogen exchange and addition to trimethoxyphenyl aldehyde.   
 
Scheme 7: Synthesis of tri-substituted phenolic ether benzhydrol analogues. 
 
 
R= allyl (24a, 25a), isobutyl (24b, 25b), isopropyl (24c, 25c), propyl (24d, 25c), hexyl 
(24e, 25e), methylcyclohexyl (24f, 25f). 
 
Reagents and Conditions: (a) RBr, K2CO3, DMF, 78 °C, overnight, 95%-99% yield. (b) n-BuLi, 
THF, -78 °C, 1.5 hours; (c) 3,4,5-trimethoxybenzaldehyde, 2 hours, 59%-65% yield. 
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3     BIOLOGY RESULT 
All analogues synthesized herein were subsequently tested for their HIF-1 
inhibition activity in a luciferase reporter assay performed by our collaborators at Emory 
University’s Winship Cancer Institute, Dr. Erwin Van Meir. This luciferase reporter 
assay is a tool used to measure expression of gene expression activated by HIF. In this 
study, the IC50 value of each analogue was tested using the HRE of VEGF gene with a 
luciferase reporter gene. The firefly luciferase reporter gene were encoded by the HIF-
responsive luciferase under the control of a promoter and tandem repeats of the 
hypoxia transcriptional response element (HRE).[33] IC50 values over 10 µM for the 
analogues were considered not potent enough for further evaluation. Therefore, 
analogues with less than 1 µM of IC50 were considered to have sufficient HIF inhibitor 
activity for further pursual. 
 
3.1 Results for Class I Analogues 
Compounds 6a, 6b, 6c, 6d, 6e, and 6f in class I were evaluated for their abilities 
to inhibit the HIF-mediated transcription activity used in the luciferase assay as 
described above. It was found that the best compound showed IC50 of about 3.8 µM 
(6c), while several had IC50 values of over 10 µM. Compared to compound 2, with IC50 
of 0.58 µM, the ortho-modified 6c was six-fold less potent. Such results suggest that 
modifications at the ortho-position likely twist the molecule due to the disturbance of π-
electron overlap and the O (hydroxyl)-C-C-C torsional angle in such a way that 
disfavors the interactions with the intended target (Table 1). 
16 
 
 
 
Compounds R IC50 (μM) 
6a 
 
>10 
6b 
 
>10 
6c  3.8 
6d  >10 
6e 
 
6.6 
6f 
 
>10 
 
Table 1: Class I Analogues 
 
3.2 Results for Class II Analogues 
For analogues in class II, 9g* have IC50 value of less 1 μM, and the other 
analogues (9a, 9b, 9c) have a lower IC50 value than most compounds in class I. When 
comparing class II and class I, the result showed that para-subtittuions exhibited better 
O
O
OHOR
17 
inhibition of HIF-1 activity than those analogues with ortho-substitutions. Specifically, 
9g* with a Boc-protected piperidine substitution on the left side inhibited completely 
HIF-1 activity most effectively with an IC50 of 0.89 μM. (Table 2).  
  
 
Compounds R IC50 (μM) 
9a 
  
1.1 
9b  3.13 
9c 
 
4.4 
9d# 
 
>5 
9e 
 
>10 
9f  >10 
9g* 
 
0.89 
 
Table 2: Class II Analogues 
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3.3 Results for Class III Analogues 
Reviewing Table 3 below and Table 2 above, the analogues of class III were seen 
to show better IC50 values than 9b, 9c and 9d# in class II. Although there are only 
minor differences in the structure, meta-substituted compounds exhibited lower IC50 
values than para-substituted compounds, especially compound 17d. The IC50 value of 
17d is 0.5 μM, which is lower than the IC50 value of compound 2, but the other 
compounds were still three- to five-fold less potent compared to compound 2. 
Temporarily, class III and class II without 9g* and 17d were not considered as potent 
HIF inhibitors due to the low biology activities. 
  
 
Compounds R IC50(μM) 
17a 
 
2.12 
17b 
 
>10 
17c  2.5 
17d 
 
0.5 
17e*  1.65 
 
Table 3: Class III Analogues. 
 
OH
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O
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3.4 Results for Class IV Analogues 
Class IV analogues shown in Table 4 can best be compared to Class I analogues 
except there are two major differences: 1) the use of a protected pyragollol on the right 
side instead of the protected catechol, and 2) a methylene that separates the oxygen 
atom of the ether and the phenyl ring on the left side. The IC50 values of three 
compounds in class IV were determined and compared, and it was found that 22c 
showed the best inhibitory activity with an IC50 value of 2.2 μM (Table 4). In contrast, 
22a* was seen to give IC50 over 10 μM. Silimar to class I, the resulting value of this 
class indicated that ortho-modications on the left might twist molecules into a less 
suitable conformation, unable to inhibit HIF-1 activity. 
 
 
Compounds R IC50 (μM) 
22a* 
 
>10 
22b  
 
5.7 
22c 
 
2.2 
 
O
O
O
OHO
R
NBoc
NBoc
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Table 4: Class IV Analogues 
 
3.5 Results for Class V Analogues 
The analogues from class V have the best IC50 values of all these five classes, 
listed in Table 5. Notably, 25b has better IC50 value than the lead, 2, at 0.58 µM. 25d 
has the same IC50 value as compound 2; thus it can be considered as the same potent 
compound. This class of compounds, featuring an additional methyl group on the left 
ring and a protected pyrogallol ion the right, yields the most active class of compounds, 
and are likely the best suited for interaction with the HIF-1 target. Following class V, 
such compounds can be considered as potent inhibitors and evaluated further (Table 
5).   
 
 
Compounds R IC50 (μM) 
25a 
 
0.62 
25b 
 
0.4 
25c 
 
0.75 
 
25d  0.58 
O
O
OH
OR
O
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25e  0.7 
25f 
 
1.2 
 
Table 5: Class V Analogues. 
 
 
4 CONCLUSIONS AND FUTURE WORK 
4.1 Structure Activity Relationship Study 
In conclusion, 27 analogs were synthesized within five different classes. 
According to the HIF inhibition results from the luciferase assay described above, a 
structure-activity relationship (SAR) was developed and analyzed. For the right side, 
protected pyragollol or protected catechol was used on the phenyl ring, and both of 
them are important to the activity. The different positions substituted on left phenyl ring 
were compared according to results from the luciferase assay, and the additional 
methyl group in Class V gave the best results. Otherwise, an important factor in 
improving inhibitory activity is the substituted para-position of Class II. Compared with 
the ortho-substituted analogues were found to be the least potent inhibitors of the three 
different types of compounds. The results suggest that ortho-substituted compounds 
may twist the molecule unfavorably, resulting in a decrease of activity. However, for the 
compounds with a Boc-protected piperidine, they exhibited better activity than there 
comparable analogues, no matter the substitution (Class II and IV).  
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4.2 Future Work 
For future work, more tri-substituted analogs with methyl group of Class V will be 
synthesized by same method. In this study, class V compounds, especially 25b were 
considered to be potent inhibitors. In the future, other similar compounds will be 
pursued, such as compounds with a methoxy group on 3’-position of the left phenyl 
ring.  
 
5 EXPERIMENTAL 
In this study, all starting materials were purchased from Sigma-Aldrich or 
Oakwood chemicals without further purification. All intermediates from this study were 
synthesized by according to literature reports. 1H amd 13C NMR spectra were recorded 
at 400 MHz and 100 MHz, respectively, on a Bruker Avance 400 NMR spectrometer. 
The solvent for dissolving all compounds in this study to record NMR was CDCl3. All 
mass spectra analyses were obtained by the mass spectratrometry facilities at Georgia 
State University.   
 
General Procedure for the Synthesis of 4a to 4f. One equivalent of 3 was dissolved in 
DMF. One equivalent of bromide and 2 equivalents of K2CO3 were added. The solution was 
stirred overnight at 78 oC, and then ethyl acetate was added. The combined organic solution was 
washed with water and brine, dried over MgSO4, and concentrated. The crude residue was 
purified by column chromatography with 100:1 hexane-ethyl acetate as the leuent. 4a-4f were 
synthesized by according to literature reports. [34-38] 
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2-(Allyloxy)benzaldehyde (4a). Yield: 98%, 1H NMR (CDCl3) δ 10.56 (s, 1H), 7.87 (d, 
1H), 7.69 (t, J = 8Hz, 1H), 7.07-6.99 (m, 2H), 6.13-6.06 (m, 1H), 5.50 (d, J = 16Hz, 1H), 5.39 
(d, J = 12Hz, 1H), 4.68 ppm (d, J = 8Hz, 2H).   
2-Isopropoxybenzaldehyde (4b). Yield: 99%, 1H NMR (CDCl3) δ 10.52 (s, 1H), 7.84 (d, 
J = 8Hz, 1H), 7.55-7.51 (m, 1H), 7.02-6.99 (m, 2H), 4.71 (t, J = 12Hz, 1H), 1.42 ppm (d, J = 
4Hz, 6H). 
2-Propoxybenzaldehyde (4c). Yield: 97%. 1H NMR (CDCl3) δ 10.52 (s, 1H), 7.82-7.80 
(m, 1H), 7.49 (t, J = 8Hz, 1H), 6.99-6.94 (m, 2H), 4.02 (t, J = 12Hz, 2H), 1.88-1.83 (m, 2H), 
1.09-1.07 ppm (m, 3H).  
2-(Hexyloxy)benzaldehyde (4d). Yield: 98%. 1H NMR (CDCl3) δ 10.51 (d, J = 4Hz, 1H), 
7.83-7.81 (m, 1H), 7.54-7.49 (m, 1H), 7.01-6.96 (m, 2H), 4.08-4.04 (m, 2H), 1.86-1.81 (m, 2H), 
1.49 (s, 2H), 1.26 (s, 4H), 0.92 ppm (t, J = 4Hz, 3H).  
2-(Cyclohexylmethoxy)benzaldehyde (4e). Yield: 97%. 1H NMR (CDCl3) δ 10.52 (d, J 
= 4Hz, 1H), 7.83-7.81 (m, 1H), 7.54-7.49 (m, 1H), 7.01-6.95 (m, 2H), 4.08-4.04 (m, 2H), 1.86-
1.81 (m, 2H), 1.49 (s, 2H), 1.35 (s, 5H), 0.91 ppm (t, J = 4Hz, 3H).  
2-(Benzyloxy)benzaldehyde (4f). Yield: 99%. 1H NMR (CDCl3) δ 10.59 (s, 1H), 7.90-
7.88 (m, 1H), 7.55 (t, J = 8Hz, 1H), 7.48-7.38 (m, 5H), 7.08 (t, J = 8Hz, 2H), 5.22 ppm (s, 2H).  
 
General Procedure for the Synthesis of 6a to 6f. One equivalent of 5 was dried for half 
an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The solution was 
cooled in a dry ice-acetone bath for 30 minutes, and then 1.1 equivalent of n-butyllithium was 
added. The reaction was stirred for 1.5 hour, followed by the dropwise addition of 1 equivalent 
of 4 in dry THF under Ar. The reaction was stirred for 2 hours at -78 0C. Then ethyl acetate was 
added followed by NH4Cl. The mixture was washed with water, dried over MgSO4, and 
concentrated. The residue was purified by column chromatography with 100:1 hexane-acetone 
as the eluent. 
(2-(Allyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (6a). Yield: 56%. 1H NMR 
(CDCl3) δ 7.29-7.26 (m, 3H), 7.00 (t, J = 20Hz, 1H), 6.91-6.89 (m, 2H), 6.83 (d, J = 8Hz, 1H), 
6.08-5.95 (m, 2H), 5.39-5.26 (m, 2H), 4.58-4.56 (m, 2H), 3.87 (d, J = 4Hz, 6H), 3.03 ppm (d, J 
= 12Hz, 1H). 13C NMR (CDCl3): δ 155.64, 148.76, 148.13, 136.00, 132.95, 132.49, 128.59, 
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127.70, 121.02, 118.79, 117.64, 111.97, 110.81, 110.00, 72.02, 68.92, 55.90, 55.82 ppm. HRMS 
(ESI) m/z calculated for C18H20O4 + Na+: 323.1259, found 323.1261.  
(2-Isopropoxyphenyl)(3,4-dimethoxyphenyl)methanol (6b). Yield: 62%. 1H NMR 
(CDCl3) δ 7.28-7.23 (m, 2H), 7.02 (s, 1H), 6.93-6.81 (m, 4H), 5.97 (s, 1H), 4.65-4.59 (m, 1H), 
3.88 (d, J = 4Hz, 6H), 3.28 (s, 1H), 1.31 (d, J = 4Hz, 3H), 1.27 ppm (d, J = 4Hz, 3H). 13C NMR 
(CDCl3): δ 154.93, 148.70, 148.04, 136.23, 132.90, 128.51, 128.00, 120.44, 118.83, 112.68, 
110.74, 109.99, 72.65, 70.01, 55.92, 55.81, 22.16, 21.98 ppm. HRMS (ESI) m/z calculated for 
C18H22O4 - OH-: 285.1485, found: 285.1473. 
(2-Propoxyphenyl)(3,4-dimethoxyphenyl)methanol (6c). Yield: 69%. 1H NMR 
(CDCl3) δ 7.28-7.23 (m, 2H), 6.97-6.88 (m, 4H), 6.84 (d, J = 4Hz, 1H), 6.03 (d, J = 4Hz, 1H), 
3.99-3.93 (m, 2H), 3.89 (d, J = 4Hz, 6H), 3.14 (d, J = 8Hz, 1H), 1.81-1.79 (m, 2H), 1.01 ppm (t, 
J = 12Hz, 3H). 13C NMR (CDCl3): δ 156.21, 148.76, 148.11, 136.02, 132.11, 128.64, 127.73, 
120.60, 118.83, 111.45, 110.79, 109.98, 72.37, 69.62, 55.91, 55.81, 22.63, 10.64 ppm. HRMS 
(ESI+) m/z calculated for C18H22O4 + Na+: 325.1416, found 325.1426. 
(2-(Hexyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (6d). Yield: 61%. 1H NMR 
(CDCl3) δ 7.28-7.22 (m, 3H), 6.97-6.82 (m, 4H), 4.02-3.97 (m, 2H), 3.93-3.89 (m, 6H), 3.17 
(d, J = 4Hz, 1H), 1.78-1.74 (m, 2H), 1.33-1.26 (m, 6H), 0.91 ppm (t, J = 16Hz, 3H). 13C NMR 
(CDCl3): δ 156.24, 148.77, 148.11, 136.04, 132.07, 128.64, 127.76, 120.57, 118.82, 111.44, 
110.75, 109.96, 72.44, 68.06, 55.88, 55.79, 31.54, 29.26, 25.76, 22.56, 14.03 ppm. HRMS 
(ESI+) m/z calculated for C21H28O4 + Na+: 367.1885, found 367.1877. 
(2-(Cyclohexylmethoxy)phenyl)(3,4-dimethoxyphenyl)methanol (6e). Yield: 55%. 
1H NMR (CDCl3) δ 7.28-7.19 (m, 4H), 6.99-6.79 (m, 3H), 6.00 (d, J = 4Hz, 1H), 3.87-3.85 
(m, 4H), 3.79-3.75 (m, 2H), 3.14 (d, J = 4Hz, 1H), 1.75-1.71 (m, 6H), 1.26 ppm (t, J = 16Hz, 
7H). 13C NMR (CDCl3): δ 156.31, 148.79, 148.12, 136.03, 132.05, 128.66, 127.82, 120.49, 
118.82, 111.34, 110.83, 109.97, 73.47, 72.42, 55.93, 55.80, 37.77, 29.90, 29.86, 26.40, 26.32, 
25.82 ppm. HRMS (ESI+) m/z calculated for C22H28O4 + Na+: 379.1885, found 379.1886. 
(2-(Benzyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (6f). Yield: 64%. 1H NMR 
(CDCl3) δ 7.33-7.26 (m, 8H), 7.03-6.97 (m, 3H), 6.84-6.80 (m, 2H), 6.05 (d, J = 4Hz, 1H), 
5.06 (s, 2H), 3.88 (s, 3H), 3.77 (s, 3H), 2.96 (d, J = 4Hz, 1H), 1.59 ppm (s, 3H). 13C NMR 
(CDCl3): δ 155.76, 148.75, 148.11, 136.58, 136.14, 132.45, 128.67, 128.58, 128.09, 127.71, 
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127.48, 121.09, 118.73, 111.95, 110.84, 110.05, 72.29, 70.18, 55.94, 55.71 ppm. HRMS (ESI+) 
m/z calculated for C22H22O4 + Na+: 373.1416, found 373.1398. 
 
General Procedure for the Synthesis of 8a to 8c. One equivalent of 7 was dissolved in 
DMF. One equivalent of bromide and 2 equivalents of K2CO3 were added. The solution was 
stirred overnight at 78 0C, and then ethyl acetate was added. The combined organic solution was 
washed with water and brine, dried over MgSO4, and concentrated. The crude residue was 
purified by column chromatography with 100:1 hexane-ethyl acetate as the eluent. 8a-8c were 
synthesized by according to literature reports. [39-40] 
4-Isobutoxybenzaldehyde (8a). Yield: 95%. 1H NMR (CDCl3) δ 9.89 (s, 1H), 7.84 (d, J = 
8Hz, 2H), 7.01 (d, J = 8Hz, 1H), 3.82 (d, J = 8Hz, 2H), 2.17-2.10 (m, 1H), 1.05 ppm (t, J = 
8Hz, 6H). 
4-(Hexyloxy)benzaldehyde (8b). Yield: 97%. 1H NMR (CDCl3) δ 9.89 (s, 1H), 7.84 (d, J 
= 8Hz, 2H), 7.01 (d, J = 8Hz, 1H), 4.06 (t, J = 8Hz, 2H), 1.86-1.79 (m, 2H), 1.51-1.36 (m, 6H), 
0.95 ppm (t, J = 8Hz, 3H). 
4-(Cyclohexylmethoxy)benzaldehyde (8c). Yield: 97%. 1H NMR (CDCl3) δ 9.90 (s, 
1H), 7.84 (d, J = 8Hz, 2H), 7.01 (d, J = 8Hz, 1H), 3.86 (d, J = 4Hz, 2H), 1.91-1.72 (m, 6H), 
1.35-1.21 (m, 3H), 1.13-1.07 ppm (m, 2H). 
 
General Procedure for the Synthesis of 9a to 9c. One equivalent of 5 was dried for half 
an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The solution was 
cooled in a dry ice-acetone bath for 30 minutes, and 1.1 equivalent of n-butyllithium was added. 
The reaction was stirred for 1.5 hour, followed by the dropwise addition of 1 equivalent of 8 in 
dry THF under Ar. The reaction was stirred for another 2 hours at -78 0C. Then ethyl acetate 
was added followed by NH4Cl. The mixture was washed with water, dried over MgSO4, and 
concentrated. The residue was purified by column chromatography with 100:1 hexane-acetone 
as the eluent. 
(4-Isobutoxyphenyl)(3,4-dimethoxyphenyl)methanol (9a). Yield: 66%. 1H NMR 
(CDCl3) δ 7.27 (d, J = 8Hz, 2H), 6.94 (s, 1H), 6.93-6.84 (m, 4H), 5.75 (s, 1H), 3.86 (d, J = 
4Hz, 6H), 3.72 (d, J = 8Hz, 2H), 2.35 (s, 1H), 2.12-2.06 (m, 1H), 1.04 ppm (d, J = 4Hz, 6H). 
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13C NMR (CDCl3): δ 158.72, 148.99, 148.33, 136.85, 136.02, 127.76, 118.79, 114.45, 110.92, 
109.70, 75.56, 74.48, 55.92, 55.85, 28.28, 19.28 ppm. HRMS (ESI+) m/z calculated for 
C19H24O4 – OH-: 299.1642, found 299.1644. 
(4-(Hexyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (9b). Yield: 71%. 1H NMR 
(CDCl3)	δ 7.30-7.27 (m, 3H), 6.95-6.82 (m, 4H), 5.79 (d, J = 4Hz, 1H), 3.96 (t, J = 8Hz, 2H), 
3.88 (d, J = 8Hz, 6H), 2.15 (d, J = 4Hz, 1H), 1.80-1.75 (m, 2H), 1.49 (t, J = 8Hz, 2H), 1.36-1.33 
(m, 4H), 0.94-0.91 ppm (m, 3H). 13C NMR (CDCl3): δ 158.63, 149.01, 148.36, 136.79, 
135.99, 127.77, 118.78, 114.44, 110.91, 109.68, 75.60, 68.05, 55.93, 55.86, 31.59, 29.25, 25.73, 
22.61, 14.04 ppm. HRMS (ESI+) m/z calculated for C21H28O4 – OH-: 327.1955, found 
327.1941. 
(4-(Cyclohexylmethoxy)phenyl)(3,4-dimethoxyphenyl)methanol (9c). Yield: 54%. 
1H NMR (CDCl3) δ 7.28 (s, 2H), 6.95-6.83 (m, 5H), 5.78 (s, 1H), 3.87 (d, J = 4Hz, 6H), 3.76 
(d, J = 4Hz, 2H), 2.14 (s, 1H), 1.89-1.70 (m, 6H), 1.33-1.20 (m, 3H), 1.10-1.01 ppm (m, 2H). 
13C NMR (CDCl3): δ 158.77, 148.99, 148.33, 136.85, 135.97, 127.76, 118.78, 114.43, 110.92, 
109.70, 75.57, 73.55, 55.93, 55.85, 37.70, 29.93, 26.54, 25.82 ppm. HRMS (ESI+) m/z 
calculated for C22H28O4 – OH-: 339.1955, found 339.1938. 
 
General Procedure for the Synthesis of 11a and 11b. One equivalent of 10 was 
dissolved in H2O. Then 1.1 equivalents of Boc2O was added in solution. The mixture was 
stirred overnight at room temperature, followed by the addition of ethyl acetate. The mixture 
was washed with water and brine, dried over MgSO4, and concentrated. 11a-11b were 
synthesized by according to literature reports. [41-42] 
Tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (11a). Yield: 99%. 1H NMR 
(CDCl3) δ 4.15 (d, J = 12Hz, 2H), 3.52 (d, J = 8Hz, 2H), 2.75-2.69 (m, 2H), 1.75-1.63 (m, 
4H), 1.49 (s, 9H), 1.20 ppm (t, J = 12Hz, 2H). 
Tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate (11b). Yield: 96%. 1H NMR 
(400 MHz, CDCl3): δ 3.89 (m, 2H), 3.51-3.48 (m, 2H), 3.16-3.14 (m, 1H), 2.54 (m, 2H), 1.54-
1.46 (m, 3H), 1.38-1.34 (m, 4H), 1.30 (s, 9H) 1.00-0.94 (m, 2H) ppm. 
  
27 
General Procedure for the Synthesis of 12*. One equivalent of 11b was dissolved in 
THF. Then 1.1 equivalents of TsCl and 1.1 equivalents of NEt3 were added in solution. The 
mixture was stirred overnight at room temperature, followed by the addition of ethyl acetate. 
The solution was washed with water and brine, dried over MgSO4, and concentrated. 
Tert-butyl 4-(2-(tosyloxy)ethyl)piperidine-1-carboxylate (12*). Yield: 86%. 1H NMR 
(CDCl3): δ 7.71 (d, J = 8Hz, 2H), 7.28 (d, J = 8Hz, 2H), 4.05-3.98 (m, 4H), 2.54 (m, 2H), 2.37 
(s, 3H), 1.51-1.44 (m, 5H), 1.38 (s, 9H) 0.99-0.94 (m, 2H) ppm. 13C NMR (CDCl3): δ 170.9, 
154.6, 144.8, 132.9, 129.8, 127.8, 79.2, 67.9, 60.2, 43.5, 35.1, 32.1, 31.5, 28.3, 21.5, 20.9 ppm.  
 
General Procedure for the Synthesis of 14a# to 14d*. One equivalent of 13 was 
dissolved in DMF. To this solution, one equivalent of bromide or 12 and 2 equivalents of 
K2CO3 were added. The solution was stirred 5 hours at 90 0C, followed by the addition of ethyl 
acetate. The combined organic solution was washed with water and brine, dried over MgSO4, 
and concentrated. The crude residue was purified by column chromatography with 100:1 
hexane-ethyl acetate as the leuent. 14a#-14d* were synthesized by according to literature 
reports. [43-44] 
1-(Allyloxy)-4-bromobenzene (14a#). Yield: 42%. 1H NMR (400 MHz, CDCl3): δ 7.37 (d, 
J = 8Hz, 2H), 6.80 (d, J = 8Hz, 2H), 6.08-5.98 (m, 1H), 5.40 (d, J = 16Hz, 2H), 5.30 (d, J = 
12Hz, 2H), 4.51 (s, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ 157.7, 132.8, 132.2, 117.9, 116.5, 
113.0, 69.0 ppm. 
1-Bromo-4-isopropoxybenzene (14b). Yield: 96%. 1H NMR (CDCl3) δ	7.47-7.43 (m, 
2H), 6.83-6.79 (m, 2H), 4.52-4.48 (m, 1H), 1.33 ppm (d, J = 8Hz, 6H). 
1-Bromo-4-propoxybenzene (14c). Yield: 98%. 1H NMR (CDCl3) δ 7.39-7.36 (m, 2H), 
6.82-6.79 (m, 2H), 3.90 (t, J = 12Hz, 2H), 1.86-1.78 (m, 2H), 1.05 (t, J = 16Hz, 3H) ppm. 
Tert-butyl 4-(2-(4-bromophenoxy)ethyl)piperidine-1-carboxylate (14d*). Yield: 85%. 
1H NMR (400 MHz, CDCl3): δ 7.34 (d, J = 8Hz, 2H), 6.74 (d, J = 8Hz, 2H), 4.07 (m, 2H), 3.95 
(t, J = 7Hz, 2H), 2.72-2.66 (m, 2H), 1.70-1.67 (m, 5H), 1.44 (s, 9H), 1.18-1.13 (m, 2H) ppm. 
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13C NMR (100 MHz, CDCl3): δ 158.0, 156.1, 154.9, 132.2, 132.1, 117.3, 116.2, 79.4, 65.6, 44.0, 
35.6, 32.9, 32.0, 28.4 ppm. 
 
General Procedure for the Synthesis of 9d# to 9g*. One equivalent of 14 was dried for 
half an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The solution 
was cooled in a dry ice-acetone bath for 30 minutes, and 1.1 equivalent of n-butyllithium was 
added. The reaction was stirred 1.5 hour, followed by the dropwise addition of 1 equivalent of 
3,4-dimethoxybenzaldehyde in dry THF under Ar. The reaction was stirred for another 2 hours 
at -78 0C. Then ethyl acetate was added followed by NH4Cl. The mixture was washed with 
water, dried over MgSO4, and concentrated. The residue was purified by column 
chromatography with 100:1 hexane-actone as the leuent. 
(4-(Allyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (9d#). Yield: 20%. 1H NMR (400 
MHz, CDCl3): δ 7.27 (d, J = 8Hz, 1H), 6.91-6.81 (m, 5H), 6.09-5.99 (m, 1H), 5.76 (s, 1H), 5.40 
(d, J = 16Hz, 2H), 5.27 (d, J = 12Hz, 2H), 4.52 (d, J = 8Hz, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 2.13 
(s, 1H). 13CNMR and HRMS are based on MG-1-15. 
(4-Isopropoxyphenyl)(3,4-dimethoxyphenyl)methanol (9e). Yield: 57%. 1H NMR 
(CDCl3) δ 7.24 (d, J = 8Hz, 2H), 6.92 (s, 1H), 6.92-6.80 (m, 4H), 5.70 (s, 1H), 4.56-4.51 (m, 
1H), 3.84 (d, J = 8Hz, 6H), 2.61 (s, 1H), 1.33 ppm (d, J = 8Hz, 6H). 13C NMR (CDCl3): δ 
157.25, 148.93, 148.25, 136.86, 136.10, 127.84, 118.79, 115.73, 110.87, 109.70, 75.47, 69.89, 
55.90, 55.82, 22.06 ppm. HRMS (ESI+) m/z calculated for C18H22O4 – OH-: 285.1485, found 
285.1484. 
(4-Propoxyphenyl)(3,4-dimethoxyphenyl)methanol (9f). Yield: 62%. 1H NMR (400 
MHz, CDCl3) δ 7.23 (d, J = 4Hz, 2H), 6.91 (d, J = 4Hz, 1H), 6.87-6.80 (m, 4H), 5.70 (s, 1H), 
3.91 (t, J = 12Hz, 2H), 3.89 (d, J = 8Hz, 6H), 2.61 (s, 1H), 1.85-1.76 (m, 2H), 1.04 ppm (t, J = 
16Hz, 3H). 13C NMR (CDCl3): δ 158.52, 148.96, 148.28, 136.92, 136.13, 127.78, 118.80, 
114.39, 110.91, 109.73, 75.47, 69.53, 55.90, 55.82, 22.59, 10.54 ppm. HRMS (ESI+) m/z 
calculated for C18H22O4 – OH-: 285.1485, found 285.1480. 
Tert-butyl 4-(2-(4-((3,4-
dimethoxyphenyl)(hydroxy)methyl)phenoxy)ethyl)piperidine-1-carboxylate (9g*). 
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Yield: 16%.  1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8 Hz, 2H), 6.91 (s, 1H), 6.83-6.79 (m, 
4H), 5.74 (s, 1H), 3.99-3.96 (m, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 2.71-2.65 (m, 2H), 2.35 (s, 1H), 
1.70-1.68 (m, 5H), 1.44 (s, 9H), 1.16-1.13 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3) δ 158.3, 
154.8, 149.0, 148.3, 136.8, 136.2, 127.7, 118.7, 114.3, 110.9, 109.6, 79.2, 76.7, 75.5, 65.3, 60.3, 
55.9, 55.8, 35.7, 32.9, 32.0, 28.4, 21.0, 14.2 ppm. HRMS is in Dr. Jalisa Holmes Ferguson’s 
data information 
 
General Procedure for the Synthesis of 16a to 16c. One equivalent of 15 was dissolved 
in DMF, followed by the addition of one equivalent of bromide and 2 equivalents of K2CO3. 
The reaction was stirred overnight at 78 0C, followed by the addition of ethyl acetate. The 
resulting mixture was washed with water and brine, dried over MgSO4, and concentrated. The 
resulting residue was purified by column chromatography with 100:1 hexane-ethyl acetate as 
the eluent. 16a-16c were synthesized by according to literature reports. [45-46] 
3-Isobutoxybenzaldehyde (16a). Yield: 96%. 1H NMR (CDCl3) δ	9.99 (s, 1H), 7.47-7.40 
(m, 3H), 7.21-7.18 (m, 1H), 3.80 (d, J = 8Hz, 2H), 2.16-2.10 (m, 1H), 1.05 ppm (t, J = 8Hz, 
6H). 
3-Isopropoxybenzaldehyde (16b). Yield: 95%. 1H NMR (CDCl3) δ 9.98 (s, 1H), 7.45-
7.39 (m, 3H), 7.18-7.15 (m, 1H), 4.68-4.62 (m, 1H), 1.38 ppm (d, J = 8Hz, 6H). 
3-Propoxybenzaldehyde (16c). Yield: 92%. 1H NMR (CDCl3) δ 9.99 (s, 1H), 7.46-7.40 
(m, 3H), 7.21-7.18 (m, 1H), 4.00 (t, J = 4Hz, 2H), 1.89-1.81 (m, 2H), 1.07 ppm (t, J = 8Hz, 3H). 
 
General Procedure for the Synthesis of 17a to 17c. One equivalent of 5 was dried for 
half an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The solution 
was cooled in a dry ice-acetone bath for 30 minutes, followed by the addition of 1.1 equivalent 
of n-butyllithium. The reaction was stirred for 1.5 hour, and then 1 equivalent of 16 in dry THF 
under Ar was added drop-wise. The reaction was stirred for another 2 hours at -78 0C, followed 
by the addition of ethyl acetate to the solution. Then NH4Cl was added to quench the reaction. 
The resulting reaction mixture was washed with water, dried over MgSO4, and concentrated. 
The residue was purified by column chromatography with 100:1 hexane-acetone as the eluent. 
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(3-Isobutoxyphenyl)(3,4-dimethoxyphenyl)methanol (17a). Yield: 68%. 1H NMR 
(CDCl3) δ 7.28-7.23 (m, 1H), 6.97-6.90 (m, 4H), 6.85-6.81 (m, 2H), 5.76 (s, 1H), 3.87 (d, J = 
4Hz, 6H), 3.72 (d, J = 4Hz, 2H), 2.33 (s, 1H), 2.10-2.07 (m, 1H), 1.04 ppm (d, J = 8Hz, 6H). 
13C NMR (CDCl3): δ 159.45, 149.04, 148.49, 145.49, 136.48, 129.43, 118.99, 118.57, 113.45, 
112.66, 110.95, 109.80, 75.94, 74.39, 55.92, 55.87, 28.32, 19.30 ppm. HRMS (ESI+) m/z 
calculated for C19H24O4 – OH-: 299.1642, found 299.1640. 
(3-Isopropoxyphenyl)(3,4-dimethoxyphenyl)methanol (17b). Yield: 72%. 1H NMR 
(CDCl3) δ 7.20 (t, J = 16Hz, 1H), 6.92-6.86 (m, 4H), 6.81-6.77 (m, 2H), 5.70 (s, 1H), 4.57-
4.51 (m, 1H), 3.88 (d, J = 8Hz, 6H), 2.70 (s, 1H), 1.29 ppm (d, J = 8Hz, 6H). 13C NMR 
(CDCl3): δ 157.94, 148.95, 148.36, 145.67, 136.57, 129.45, 118.97, 118.64, 114.62, 114.09, 
110.90, 109.75, 75.80, 69.76, 55.89, 55.81, 22.06, 22.04 ppm. HRMS (ESI+) m/z calculated for 
C18H22O4 – OH-: 285.1485, found 285.1481. 
(3-Propoxyphenyl)(3,4-dimethoxyphenyl)methanol (17c). Yield: 67%. 1H NMR 
(CDCl3) δ 7.28-7.22 (m, 1H), 6.98-6.84 (m, 4H), 6.82-6.79 (m, 2H), 5.71 (s, 1H), 3.90 (t, J = 
8Hz, 2H), 3.84 (d, J = 8Hz, 2H), 2.66 (d, J = 4Hz, 1H), 1.83-1.77 (m, 2H), 1.04 ppm (t, J = 
8Hz, 3H). 13C NMR (CDCl3): δ 159.26, 149.00, 148.42, 145.61, 136.58, 129.41, 118.98, 
118.64, 113.37, 112.68, 110.95, 109.82, 75.83, 69.45, 55.90, 55.84, 22.61, 10.56 ppm. HRMS 
(ESI+) m/z calculated for C18H22O4 – OH-: 285.1485, found 285.1483. 
 
General Procedure for the Synthesis of 19a and 19b. One equivalent of 18 was 
dissolved in DMF. To this solution, one equivalent of bromide and 2 equivalents of K2CO3 were 
added. The solution was stirred 5 hours at 90 0C, followed by the addition of ethyl acetate. The 
combined organic solution was washed with water and brine, dried over MgSO4, and 
concentrated. The crude residue was purified by column chromatography with 100:1 hexane-
ethyl acetate as the eluent. 19a-19b* were synthesized by according to literature reports. [47-48] 
1-(Allyloxy)-3-bromobenzene (19a). Yield: 95%. 1H NMR (CDCl3) δ	7.24-7.14 (m, 3H), 
6.89-6.86 (m, 1H), 6.14-6.04 (m, 1H), 5.48-5.44 (m, 1H), 5.39-5.35 (m, 1H), 4.55-4.52 ppm (m, 
2H). 
1-Bromo-3-(hexyloxy)benzene (19b)*. Yield: 65%. 1H NMR (400 MHz, CDCl3): δ 7.13 (t, 
J = 8Hz, 1H), 7.07-7.06 (m, 2H), 6.83 (d, J = 8Hz, 2H), 3.93 (t, J = 7Hz, 2H), 1.77 (q, 2H), 
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1.47-1.44 (m, 2H), 1.36-1.34 (m, 4H), 0.93 (t, J = 7Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): 
δ 159.9, 130.4, 123.5, 122.8, 117.7, 113.5, 68.2, 31.5, 29.1, 25.7, 22.6, 14.0 ppm. 
 
General Procedure for the Synthesis of 17d and 17e. One equivalent of 19 was dried 
for half an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The 
solution was cooled in a dry ice-acetone bath for 30 minutes, and 1.1 equivalent of n-
butyllithium was added. The reaction was stirred 1.5 hour, followed by the dropwise addition of 
1 equivalent of 3,4-dimethoxybenzaldehyde in dry THF under Ar. The reaction was stirred for 
another 2 hours at -78 0C. Then ethyl acetate was added followed by NH4Cl. The mixture was 
washed with water, dried over MgSO4, and concentrated. The residue was purified by column 
chromatography with 100:1 hexane-actone as the eluent. 
(3-(Allyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (17d). Yield: 64%. 1H NMR 
(CDCl3) δ 7.27 (t, J = 12Hz, 1H), 6.99-6.89 (m, 4H), 6.84 (d, J = 8Hz, 2H), 6.10-6.03 (m, 1H), 
5.78 (s, 1H), 5.44 (d, J = 4Hz, 1H), 5.39 (d, J = 4Hz, 1H), 4.55-4.53 (m, 2H), 3.88 (d, J = 8Hz, 
6H), 2.24 ppm (s, 1H). 13C NMR (CDCl3): δ 158.68, 148.99, 148.41, 145.72, 136.56, 133.29, 
129.42, 119.00, 118.98, 117.66, 113.56, 112.90, 110.96, 109.82, 75.73, 68.74, 55.90, 55.83 
ppm. HRMS (ESI+) m/z calculated for C18H20O4 – OH-: 283.1329, found 283.1326. 
(3-(Hexyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (17e*). Yield: 93%. 1H NMR 
(400 MHz, CDCl3): δ 7.22 (t, J = 8Hz, 1H), 6.93-6.86 (m, 4H), 6.82-6.77 (m, 2H), 5.74 (s, 1H), 
3.92 (t, J = 7Hz, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 2.30 (bs, 1H), 1.75 (p, J = 7Hz, 2H), 1.45-1.40 
(m, 2H), 1.34-1.30 (m, 4H), 0.90 (t, J = 7Hz, 1H)  ppm. 13C NMR (100 MHz, CDCl3): δ 159.4, 
149.1, 148.5, 145.6, 136.5, 129.5, 119.0, 118.6, 113.5, 112.7, 111.0, 109.8, 76.0, 68.0, 56.0, 
55.9, 31.7, 29.3, 25.8, 22.7, 14.1 ppm. HRMS is in Dr. Jalisa Holmes Ferguson’s data 
information. 
 
General Procedure for the Synthesis of 21a to 21c. One equivalent of 20 was dissolved 
in DMF, followed by the addition of 1 equivalent of alcohol and 2 equivalents of NaH. The 
reaction was stirred overnight at 0 0C to room temperature. To this solution, ethyl acetate was 
added. The resulting mixture was washed with water and brine, dried over MgSO4, and 
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concentrated. The residue was purified by column chromatography with 100:1 hexane-ethyl 
acetate as the eluent. 21a-21c were synthesized by according to literature reports.[49-51] 
1-Bromo-2-(phenoxymethyl)benzene (21a). Yield: 99%. 1H NMR (400 MHz, CDCl3): δ 
7.69-7.65 (m, 2H), 7.43-7.39 (m, 3H), 7.26 (t, J = 8Hz, 1H), 7.11-7.07 (m, 3H), 5.23 (s, 2H) 
ppm. 13C NMR (100 MHz, CDCl3): δ 158.5, 136.4, 132.6, 129.6, 129.2, 128.9, 127.6, 122.3, 
121.2, 114.9, 69.3 ppm. 
Tert-butyl 4-(((2-bromobenzyl)oxy)methyl)piperidine-1-carboxylate (21b). Yield: 
96%. 1H NMR (CDCl3) δ 7.56-7.54 (m, 1H), 7.49-7.47 (m, 1H), 7.33 (t, J = 16Hz, 1H), 7.18 
(t, J = 12Hz, 1H), 4.57 (s, 2H), 3.42 (d, J = 8Hz, 2H), 1.80-1.77 (m, 4H), 1.48 (s, 9H), 1.28-1.15 
ppm (m, 5H).  
Tert-butyl 4-(2-((2-bromobenzyl)oxy)ethyl)piperidine-1-carboxylate (21c). Yield: 
96%. 1H NMR (CDCl3) δ 7.56 (d, J = 4Hz, 1H), 7.47 (d, J = 8Hz, 1H), 7.33 (t, J = 16Hz, 1H), 
7.17 (t, J = 12Hz, 1H), 4.57 (s, 2H), 3.62 (t, J = 12Hz, 2H), 1.70-1.59 (m, 6H), 1.47 (t, J = 
16Hz, 9H), 1.13 ppm (d, J = 12Hz, 3H). 
 
General Procedure for the Synthesis of 22a to 22c. One equivalent of 21 was dried for 
half an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The solution 
was cooled in a dry ice-acetone bath for 30 minutes, followed by the addition of 1.1 equivalent 
of n-butyllithium. The reaction was stirred for 1.5 hour, and then 1 equivalent of 3,4,5-
trimethoxybenzaldehyde in dry THF under Ar was added drop-wise. The reaction was stirred 
for another 2 hours at -78 0C, followed by the addition of ethyl acetate to the solution. Then 
NH4Cl was added to quench the reaction. The resulting reaction mixture was washed with 
water, dried over MgSO4, and concentrated. The residue was purified by column 
chromatography with 100:1 hexane-acetone as the leuent.  
(2-(Phenoxymethyl)phenyl)(3,4,5-trimethoxyphenyl)methanol (22a*). Yield: 58%. 
1H NMR (CDCl3) δ 7.44 (d, J = 4Hz, 1H), 7.33-7.28 (m, 5H), 7.00 (t, J = 4Hz, 1H), 6.92-6.90 
(m, 2H), 6.55 (s, 2H), 6.07 (d, J = 4Hz, 1H), 5.02-4.94 (dd, J = 12Hz, 2H), 3.86 (d, J = 4Hz, 
3H), 3.72 (d, J = 4Hz, 6H), 2.92 ppm (d, J = 4Hz, 1H). 13C NMR and HRMS are in Dr. Jalisa 
Holmes Ferguson’s data information. 
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Tert-butyl 4-(((2-(hydroxy(3,4,5-
trimethoxyphenyl)methyl)benzyl)oxy)methyl)piperidine-1-carboxylate (22b). 
Yield: 55%. 1H NMR (CDCl3) δ 7.35-7.23 (m, 4H), 6.61 (s, 2H), 5.95 (d, J = 4Hz, 1H), 4.61 
(d, J = 12Hz, 1H), 4.40 (d, J = 12Hz, 1H), 4.17-4.12 (m, 2H), 3.86 (s, 3H), 3.81 (s, 6H), 3.34 (t, 
J = 4Hz, 2H), 2.67 (t, J = 8Hz, 2H), 1.79-1.69 (m, 4H), 1.46 (s, 9H), 1.17-1.13 ppm (m, 2H). 
13C NMR (CDCl3):	δ 154.80, 153.12,143.32, 138.44, 136.98, 135.29, 130.76, 128.94, 128.88, 
127.93, 103.57, 79.36, 75.51, 73.81, 72.46, 60.89, 56.09, 43.36, 36.50, 29.07, 28.45 ppm. 
HRMS (ESI+) m/z calculated for C28H39NO7 – OH-: 484.2694, found 484.2691. 
Tert-butyl 4-(2-((2-(hydroxy(3,4,5-
trimethoxyphenyl)methyl)benzyl)oxy)ethyl)piperidine-1-carboxylate (22c). Yield: 
59%. 1H NMR (CDCl3) δ 7.36-7.24 (m, 4H), 6.62 (s, 2H), 5.95 (d, J = 4Hz, 1H), 4.60 (d, J = 
8Hz, 1H), 4.39 (d, J = 8Hz, 1H), 4.24 (d, J = 4Hz, 1H), 4.05 (d, J = 8Hz, 2H), 3.87 (s, 3H), 3.79 
(s, 6H), 3.34 (t, J = 4Hz, 2H), 3.57-3.52 (m, 2H), 2.67 (t, J = 12Hz, 2H), 1.71-1.54 (m, 5H), 
1.46 (s, 9H), 1.12-1.09 ppm (m, 2H). 13C NMR (CDCl3): δ 154.85, 153.10, 143.45, 138.50, 
136.94, 135.39, 130.78, 129.10, 128.91, 127.92, 103.51, 79.26, 73.88, 72.32, 68.15, 60.90, 
56.09, 43.81, 36.13, 32.90, 32.06, 28.46 ppm. HRMS (ESI+) m/z calculated for C29H41NO7 – 
OH-: 498.2850, found 498.2827. 
 
General Procedure for the Synthesis of 24a to 24f. One equivalent of 23 was dissolved 
in DMF. To this solution, 1 equivalents of RBr and 2 equivalents of K2CO3 were added. The 
reaction was stirred overnight at 78 0C, followed by the addition of ethyl acetate. The resulting 
mixture was washed with water and brine, dried over MgSO4, and concentrated. The resulting 
residue was purified by column chromatography with 100:1 hexane-ethyl acetate. 24a-24f were 
synthesized by according to literature reports. [52-56] 
1-(Allyloxy)-4-bromo-2-methylbenzene (24a). Yield: 97%. 1H NMR (CDCl3) δ 7.29-
7.24 (m, 2H), 6.70 (d, J = 8Hz, 1H), 6.11-6.04 (m, 1H), 5.47 (d, J = 4Hz, 1H), 5.33 (d, J = 4Hz, 
1H), 4.55-4.53 (m, 2H), 2.26 ppm (s, 3H). 
4-Bromo-1-isobutoxy-2-methylbenzene (24b). Yield: 96%. 1H NMR (CDCl3) δ 7.29-
7.24 (m, 2H), 6.70 (d, J = 8Hz, 1H), 6.11-6.04 (m, 1H), 5.47 (d, J = 4Hz, 1H), 5.33 (d, J = 4Hz, 
1H), 4.55-4.53 (m, 2H), 2.26 ppm (s, 3H). 
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4-Bromo-1-isopropoxy-2-methylbenzene (24c). Yield: 95%. 1H NMR (CDCl3) δ 7.28-
7.25 (m, 2H), 6.69 (d. J = 8Hz, 1H), 3.73 (d, J = 4Hz, 2H), 2.24 (s, 3H), 2.19-2.09 (m, 1H), 1.08 
ppm (d, J = 4Hz, 6H). 
4-Bromo-2-methyl-1-propoxybenzene (24d). Yield: 97%. 1H NMR (CDCl3) δ 7.25 (d, J 
= 8Hz, 2H), 6.68 (d, J = 4Hz, 1H), 3.91 (t, J = 8Hz, 2H), 2.21 (s, 3H), 1.90-1.80 (m, 2H), 1.08 
ppm (t, J = 8Hz, 3H). 
4-Bromo-1-(hexyloxy)-2-methylbenzene (24e). Yield: 99%. 1H NMR (CDCl3) δ	7.24 
(d, J = 4Hz, 2H), 6.69 (d, J = 4Hz, 1H), 3.91 (t, J = 4Hz, 2H), 2.22 (s, 3H), 1.86-1.79 (m, 2H), 
1.52-1.48 (m, 1H), 1.40-1.33 (m, 5H), 0.92 ppm (s, 3H). 
4-Bromo-1-(cyclohexylmethoxy)-2-methylbenzene (24f). Yield: 92%. 1H NMR 
(CDCl3) δ 7.28-7.24 (m, 2H), 6.67 (d, J = 4Hz, 1H), 3.73 (d, J = 4Hz, 2H), 2.21 (s, 3H), 1.89-
1.72 (m, 5H), 1.34-1.23 (m, 4H), 1.11-1.08 ppm (m, 2H). 
 
General Procedure for Synthesis of 25a to 25f. One equivalent of 24 was dried for half 
an hour under oil-vacuum pump, and dissolved in dry THF under argon gas. The solution was 
cooled in a dry ice-acetone bath for 30 minutes, followed by the addition of 1.1 equivalent of n-
butyllithium. The reaction was stirred for 1.5 hour, and then 1 equivalent of 3,4,5-
trimethoxybenzaldehyde in dry THF under Ar was added drop-wise. The reaction was stirred 
for another 2 hours at -78 0C, followed by the addition of ethyl acetate to the solution. Then 
NH4Cl was added to quench the reaction. The resulting reaction mixture was washed with 
water, dried over MgSO4, and concentrated. The residue was purified by column 
chromatography with 100:1 hexane-acetone as the leuent.  
(4-(Allyloxy)-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25a). Yield: 60%. 
1H NMR (CDCl3) δ 7.16-7.15 (m, 2H), 6.79 (d, J = 4Hz, 1H), 6.63 (s, 2H), 6.12-6.05 (m, 1H), 
5.71 (s, 1H), 5.46 (dd, J = 8Hz, 1H), 5.31-5.27 (m, 1H), 4.56-4.54 (m, 2H), 3.86-3.85 (m, 9H), 
2.26 (s, 3H), 2.21 ppm (s, 1H). 13C NMR (CDCl3): δ 156.35, 153.21, 139.75, 137.11, 135.64, 
133.50, 129.16, 127.17, 125.01, 117.00, 111.12, 103.39, 75.97, 68.77, 60.83, 56.11, 16.41 ppm. 
HRMS (ESI+) m/z calculated for C20H24O5 – OH-: 327.1591, found 327.1592. 
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(4-Isobutoxy-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25b). Yield: 59%. 
1H NMR (CDCl3) δ 7.15-7.13 (m, 2H), 6.77 (d, J = 8Hz, 1H), 6.64 (s, 2H), 5.71 (d, J = 4Hz, 
1H), 3.86 (d, J = 4Hz, 9H), 3.73 (d, J = 8Hz, 2H), 2.24 (s, 3H), 2.15-2.11 (m, 2H), 1.05 ppm (d, 
J = 8Hz, 6H). 13C NMR (CDCl3): δ156.84, 153.14, 139.99, 136.99, 135.33, 128.99, 126.94, 
125.02, 110.62, 103.38, 75.92, 74.35, 60.80, 56.07, 28.43, 19.33, 16.34 ppm. HRMS (ESI+) m/z 
calculated for C21H28O5 – OH-: 343.1904, found 343.1905. 
(4-Isopropoxy-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25c). Yield: 
43%. 1H NMR (CDCl3) δ 7.16-7.11 (m, 2H), 6.81 (d, J = 8Hz, 1H), 6.64 (s, 2H), 5.72 (s, 1H), 
4.54-4.51 (m, 1H), 3.86 (t, J = 4Hz, 9H), 2.21 (s, 3H), 2.13 (d, J = 4Hz, 1H), 1.35 ppm (d, J = 
4Hz, 6H). 13C NMR (CDCl3): δ 153.21, 139.74, 135.28, 129.27, 124.97, 112.82, 112.50, 
104.27, 103.40, 76.04, 70.28, 60.84, 56.12, 56.03, 22.25, 16.56 ppm. HRMS (ESI+) m/z 
calculated for C20H26O5 – OH-: 329.1747, found 329.1732. 
(3-Methyl-4-propoxyphenyl)(3,4,5-trimethoxyphenyl)methanol (25d). Yield: 69%. 1H 
NMR (CDCl3) δ 7.13 (t, J = 8Hz, 2H), 6.78 (d, J = 8Hz, 1H), 6.63 (s, 2H), 5.70 (s, 1H), 3.93 
(t, J = 8Hz, 2H), 3.88 (s, 9H), 2.34 (s, 1H), 2.23 (s, 3H), 1.86-1.81 (m, 2H), 1.07 ppm (t, J = 
8Hz, 3H). 13C NMR (CDCl3): δ 156.65, 153.17, 139.88, 137.04, 135.30, 129.03, 127.02, 
125.03, 110.75, 103.38, 75.97, 69.54, 60.82, 56.10, 22.71, 16.33, 10.66 ppm. HRMS (ESI+) m/z 
calculated for C20H26O5 – OH-: 329.1747, found 329.1747. 
(4-(Hexyloxy)-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25e). Yield: 63%. 
1H NMR (CDCl3) δ 7.15-7.13 (m, 2H), 6.78 (d, J = 8Hz, 1H), 6.64 (s, 2H), 5.72 (s, 1H), 3.97 
(t, J = 12Hz, 2H), 3.85 (d, J = 4Hz, 9H), 2.23 (s, 3H), 2.19 (s, 1H), 1.83-1.77 (m, 2H), 1.51-1.47 
(m, 2H), 1.38-1.34 (m, 4H), 0.92 ppm (t, J = 12Hz, 3H). 13C NMR (CDCl3): δ	156.92, 153.21, 
139.79, 137.09, 135.21, 129.02, 127.06, 125.03, 110.72, 103.37, 76.04, 68.05, 60.84, 56.12, 
31.57, 29.30, 25.82, 22.62, 16.36, 14.03 ppm. HRMS (ESI+) m/z calculated for C23H32O5 – 
OH-: 371.2217, found 371.2219. 
(4-(Cyclohexylmethoxy)-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25f). 
Yield: 62%. 1H NMR (CDCl3) δ 7.15-7.13 (m, 2H), 6.77 (d, J = 8Hz, 1H), 6.64 (s, 2H), 5.72 (d, 
J = 4Hz, 1H), 3.89 (s, 9H), 3.76 (d, J = 8Hz, 2H), 2.23 (s, 3H), 2.15 (d, J = 4Hz, 1H), 1.90-1.74 
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(m, 6H), 1.25-1.08 ppm (m, 5H). 13C NMR (100 MHz, CDCl3): δ 156.91, 153.14, 139.96, 
136.99, 135.26, 128.97, 126.97, 125.01, 110.62, 103.36, 75.94, 73.45, 60.80, 56.08, 37.84, 
29.97, 26.57, 25.89, 16.38 ppm. HRMS (ESI+) m/z calculated for C24H32O5 – OH-: 383.2217, 
found 383.2213. 
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APPENDICES  
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Class II: Para-phenolic ether benzhydrol analogues 
4-isobutoxybenzaldehyde (8a).  
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Tert-butyl 4-(2-(4-bromophenoxy)ethyl)piperidine-1-carboxylate (14d)* Spectra will 
be in Jalisa Ferguson’s information. 
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(4-(cyclohexylmethoxy)phenyl)(3,4-dimethoxyphenyl)methanol (9c) 
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 (3,4-dimethoxyphenyl)(4-isopropoxyphenyl)methanol (9e) 
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(3,4-dimethoxyphenyl)(4-propoxyphenyl)methanol (9f) 
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tert-butyl 4-(2-(4-((3,4-dimethoxyphenyl)(hydroxy)methyl)phenoxy)ethyl)piperidine-1-
carboxylate (9g)* Spectra will be in Jalisa Ferguson’s information. 
 
 
Class III: Meta-phenolic ether benzhydrol analogues 
3-isobutoxybenzaldehyde (16a) 
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1-(allyloxy)-3-bromobenzene	(19a).	
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1-bromo-3-(hexyloxy)benzene (19b)* 
(3,4-dimethoxyphenyl)(3-isobutoxyphenyl)methanol (17a) 
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(3,4-dimethoxyphenyl)(3-isopropoxyphenyl)methanol (17b) 
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(3,4-dimethoxyphenyl)(3-propoxyphenyl)methanol (17c) 
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(3-(allyloxy)phenyl)(3,4-dimethoxyphenyl)methanol (17d)	
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(3,4-dimethoxyphenyl)(3-(hexyloxy)phenyl)methanol (17e)* Spectra will be in Jalisa 
Ferguson’s information. 
 
Class IV : Ortho-benzyl ether benzhydrol  analogues. 
1-bromo-2-(phenoxymethyl)benzene (21a) 
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tert-butyl 4-(((2-bromobenzyl)oxy)methyl)piperidine-1-carboxylate (21b) 
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(2-(phenoxymethyl)phenyl)(3,4,5-trimethoxyphenyl)methanol (22a)* 
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tert-butyl 4-(((2-(hydroxy(3,4,5-trimethoxyphenyl)methyl)benzyl)oxy)methyl)piperidine-1-
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468 470 472 474 476 478 480 482 484 486 488 490 492 494 496 498
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tert-butyl 4-(2-((2-(hydroxy(3,4,5-trimethoxyphenyl)methyl)benzyl)oxy)ethyl)piperidine-1-
carboxylate (22c) 
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LY_I_38_ESIPOS_BWANG_012017 #174-182 RT: 2.43-2.54 AV: 9 NL: 1.29E8
T: FTMS + p ESI Full ms [100.00-1000.00]
370 380 390 400 410 420 430 440 450 460 470 480 490 500 510 520 530
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Class V: Tri-substituted phenolic ether benzhydrol analogues  
 
1-(allyloxy)-4-bromo-2-methylbenzene (24a) 
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4-bromo-1-isobutoxy-2-methylbenzene (24b) 
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4-bromo-1-isopropoxy-2-methylbenzene (24c) 
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4-bromo-2-methyl-1-propoxybenzene (24d) 
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4-bromo-1-(hexyloxy)-2-methylbenzene (24e) 
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4-bromo-1-(cyclohexylmethoxy)-2-methylbenzene (24f) 
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(4-(allyloxy)-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25a) 
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LYI_I_68_ESIPOS_BWANG_11102016 #121-135 RT: 1.94-2.14 AV: 15 NL: 5.18E7
T: FTMS + p ESI Full ms [50.00-1000.00]
316 318 320 322 324 326 328 330 332 334 336 338 340
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(4-isobutoxy-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25b) 
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LY_I_69_ESIPOS_BWANG_021017 #132-140 RT: 1.86-1.97 AV: 9 NL: 1.43E8
T: FTMS + p ESI Full ms [100.00-1000.00]
338 340 342 344 346 348 350 352 354 356 358 360 362 364 366 368 370 372 374
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(4-isopropoxy-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25c) 
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LY_I_62_ESIPOS_BWANG_012017 #145-151 RT: 2.04-2.13 AV: 7 NL: 1.49E8
T: FTMS + p ESI Full ms [100.00-1000.00]
314 316 318 320 322 324 326 328 330 332 334 336 338 340 342 344 346
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(3-methyl-4-propoxyphenyl)(3,4,5-trimethoxyphenyl)methanol (25d) 
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LYI_II_3_ESIPOS_BWANG_11102016 #129-135 RT: 2.01-2.10 AV: 7 NL: 1.10E8
T: FTMS + p ESI Full ms [50.00-1000.00]
310 315 320 325 330 335 340 345 350 355
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(4-(hexyloxy)-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25e) 
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LYI_I_61_ESIPOS_BWANG_11102016 #130-139 RT: 2.10-2.23 AV: 10 NL: 6.43E6
T: FTMS + p ESI Full ms [50.00-1000.00]
355 360 365 370 375 380 385 390 395 400 405 410
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(4-(cyclohexylmethoxy)-3-methylphenyl)(3,4,5-trimethoxyphenyl)methanol (25f) 
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LY_I_110_ESIPOS_BWANG_021017 #140-147 RT: 1.98-2.07 AV: 8 NL: 1.84E7
T: FTMS + p ESI Full ms [100.00-1000.00]
374 376 378 380 382 384 386 388 390 392
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